人类免疫缺陷病毒（HIV）的病原体总结声明，包括人类嗜T淋巴细胞病毒III型（HTLV-III）、淋巴结病相关病毒（LAV）、HIV-1和HIV-2。 - Suppr | 超能文献

Agent summary statement for human immunodeficiency viruses (HIVs) including HTLV-III, LAV, HIV-1, and HIV-2.

出版信息

MMWR Suppl. 1988 Apr 1;37(4):1-17.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Agent summary statement for human immunodeficiency viruses (HIVs) including HTLV-III, LAV, HIV-1, and HIV-2.人类免疫缺陷病毒（HIV）的病原体总结声明，包括人类嗜T淋巴细胞病毒III型（HTLV-III）、淋巴结病相关病毒（LAV）、HIV-1和HIV-2。

MMWR Suppl. 1988 Apr 1;37(4):1-17.

2

Human T-lymphotropic virus type III/lymphadenopathy-associated virus: agent summary statement.人类嗜T淋巴细胞病毒III型/淋巴结病相关病毒：病原体总结声明。

MMWR Morb Mortal Wkly Rep. 1986 Aug 29;35(34):540-2, 547-9.

3

Leads from the MMWR. Human T-lymphotropic virus type III/lymphadenopathy-associated virus: agent summary statement.《发病率与死亡率周报》报道。人类嗜T淋巴细胞病毒III型/淋巴结病相关病毒：病原体总结声明。

JAMA. 1986 Oct 10;256(14):1857, 1861, 1868 passim.

4

[HIV infection and prevention in dental practice].[牙科诊疗中的HIV感染与预防]

Minerva Stomatol. 1988 Dec;37(12):1015-20.

5

Occupationally acquired human immunodeficiency virus infections in laboratories producing virus concentrates in large quantities: conclusions and recommendations of an expert team convened by the director of the National Institutes of Health (NIH). Reported by Division of Safety, National Institutes of Health.在大量生产病毒浓缩物的实验室中通过职业途径获得的人类免疫缺陷病毒感染：美国国立卫生研究院（NIH）主任召集的一个专家小组的结论与建议。由美国国立卫生研究院安全司报告。

MMWR Suppl. 1988 Apr 1;37(4):19-22.

6

Biosafety in acquired immunodeficiency syndrome (AIDS) studies using nonhuman primates.

J Med Primatol. 1987;16(2):131-8.

7

Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings.更新：医疗保健机构中预防人类免疫缺陷病毒、乙型肝炎病毒及其他血源性病原体传播的通用防护措施。

MMWR Morb Mortal Wkly Rep. 1988 Jun 24;37(24):377-82, 387-8.

8

Infection control measures for human immunodeficiency virus (HIV): universal precautions.人类免疫缺陷病毒（HIV）的感染控制措施：通用防护措施

J Okla State Med Assoc. 1988 Sep;81(9):575-6.

9

Leads from the MMWR. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings.

JAMA. 1988;260(4):462-5.

10

[Guidelines for the management of patients infected by the human immunodeficiency virus].[人类免疫缺陷病毒感染患者的管理指南]

Rev Invest Clin. 1988 Jan-Mar;40(1):47-63.

引用本文的文献

1

Viral pandemics and oral health: Lessons learned from HIV to SARS-CoV-2.病毒性大流行与口腔健康：从艾滋病毒到新冠病毒的经验教训。

Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 Feb;131(2):149-153. doi: 10.1016/j.oooo.2020.10.022. Epub 2020 Nov 5.

2

CCN1 is an opsonin for bacterial clearance and a direct activator of Toll-like receptor signaling.CCN1 是一种调理素，可促进细菌清除，并直接激活 Toll 样受体信号通路。

Nat Commun. 2020 Mar 6;11(1):1242. doi: 10.1038/s41467-020-15075-5.

3

Occupational exposures to blood and risk of HIV transmission in a general hospital (1986-88).综合医院职业暴露于血液与HIV传播风险（1986 - 1988年）

Eur J Epidemiol. 1990 Mar;6(1):67-70. doi: 10.1007/BF00155552.